Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
Truxima Rituximab Cancelled
Atriance Nelarabine Cancelled
Demylocan Decitabine CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Latuda lurasidone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Talzenna talazoparib Breast cancer CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Zolinza vorinostat Cutaneous T-cell lymphoma CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Xofluza baloxavir marboxil Influenza CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
TBD Rituximab Cancelled
Xarelto Rivaroxaban (granules for oral suspension) Venous Thromboembolic Events CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Adcetris brentuximab vedotin Hodgkin lymphoma Withdrawn